Serum neurofilament light protein as a biomarker across the cognitive decline continuum: a cross-sectional study from an Indian cohort
Aging Clinical and Experimental Research · 2026
DOI: 10.1007/s40520-026-03381-9 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Aging Clinical and Experimental Research, 2026. Verfasst von Akshata Rao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine National Centre of Aging All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Neurofilament Proteins, Cognitive Dysfunction, Alzheimer Disease. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The Alzheimer's disease (AD) continuum spans from healthy aging to subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia. Serum Neurofilament Light Protein (NfL) is a potential non-invasive biomarker for neurodegeneration. This study evaluates serum NfL across the cognitive decline continuum in an Indian cohort. AIMS: To assess serum NfL as a biomarker for early and progressive neurodegeneration, including its diagnostic utility in SCD, MCI, and AD. METHODS: This case-control study included 129 participants: 28 cognitively normal older adults (HC), 32 with SCD, 33 with MCI, and 36 with AD. Serum NfL levels were measured using Simoa® technology. The association of NfL with cognitive decline was analyzed using a Generalized Linear Model (GLM) adjusted for age and sex, and receiver operating characteristic (ROC) curves assessed diagnostic performance. RESULTS: Serum NfL median levels progressively increased across groups: HC (21.1 pg/mL), SCD (28.94 pg/mL), MCI (35.5 pg/mL), and AD (48.64 pg/mL). Compared to HC, NfL levels were significantly higher in SCD (adjusted coefficient: 0.59, p = 0.004), MCI (0.72, p = 0.001), and AD (1.13, p < 0.001). ROC analysis showed good discrimination: AUC was 0.795 for SCD vs. HC, 0.908 for MCI vs.HC, and 0.941 for AD vs. HC. DISCUSSION: The study demonstrates a clear association between rising serum NfL levels and advancing cognitive decline. CONCLUSIONS: Serum NfL demonstrated potential as a sensitive and non-invasive biomarker for early detection and staging of cognitive decline. The establishment of population-specific cut-offs within an Indian cohort contributes to global efforts toward standardizing blood-based biomarkers for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatric Medicine National Centre of Aging All India Institute of Medical Sciences, New Delhi, India.
- Department of Biophysics All India Institute of Medical Sciences, New Delhi, India.
- Rajagiri Hospital, Kochi, Kerala, India.
- Artemis Hospital, Gurgaon, India.
- Department of Geriatric Medicine National Centre of Aging All India Institute of Medical Sciences, New Delhi, India. drprasun.geriatrics@gmail.com.
Zitieren
APA
Rao, A., Anwar, M., Rao, A. R., Painkra, B., Kiruthika, S., Kumar, S., Yadav, Y., Dey, A. B., Dey, S., & Chatterjee, P. (2026). Serum neurofilament light protein as a biomarker across the cognitive decline continuum: a cross-sectional study from an Indian cohort. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-026-03381-9
Vancouver
Rao A, Anwar M, Rao AR, Painkra B, Kiruthika S, Kumar S, et al. Serum neurofilament light protein as a biomarker across the cognitive decline continuum: a cross-sectional study from an Indian cohort. Aging Clinical and Experimental Research. 2026. doi:10.1007/s40520-026-03381-9
BibTeX
@article{Rao2026,
author = {Rao, Akshata and Anwar, Masroor and Rao, Abhijith R and Painkra, Bhawana and Kiruthika, Sakthi and Kumar, Sunil and Yadav, Yudhishthir and Dey, Aparajit Ballav and Dey, Sharmistha and Chatterjee, Prasun},
title = {Serum neurofilament light protein as a biomarker across the cognitive decline continuum: a cross-sectional study from an Indian cohort},
journal = {Aging Clinical and Experimental Research},
year = {2026},
doi = {10.1007/s40520-026-03381-9}
}
EUVIMED